A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults

This study has been completed.

Sponsor:

Information provided by:

DynPort Vaccine Company LLC, A CSC Company

ClinicalTrials.gov Identifier:

NCT00057525

First received: April 3, 2003

Last updated: June 29, 2011

Last verified: June 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	August 2004
Primary Completion Date:	April 2004 (Final data collection date for primary outcome measure)

No publications provided by DynPort Vaccine Company LLC, A CSC Company

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Brown BK, Cox J, Gillis A, VanCott TC, Marovich M, Milazzo M, Antonille TS, Wieczorek L, McKee KT Jr, Metcalfe K, Mallory RM, Birx D, Polonis VR, Robb ML. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS One. 2010 Nov 5;5(11):e13849.

To Top